Avanos Medical, Inc.

Avanos Medical, Inc.

AVNSNYSE / NASDAQHealthcareSmall cap

$24.99+$0.01 (0.0%)

Last close · Data as of Jul 24, 2026

Market cap
$1.2B
Revenue
$701.2M
Net margin
-10.4%
ROCE
-6.6%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Avanos Medical, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 24 Jul 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change +$0.01 (0.0%) from $25 to $25 · Last close Jul 24, 2026

Best weekday to invest, historically

The same weekly amount in AVNS, bought on each weekday since 2021.

News & filings

What Avanos Medical filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 72.9 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 2.15 times current liabilities.
  • Prices are as of 24 Jul 2026; price-based points are paused until newer prices arrive.

Prices to the 24 Jul 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.

Read moreShow less

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Sector
Healthcare
Shares outstanding
46.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.2B
P/B
1.5x
EV / Sales
1.7x
P/S
1.7x
52-week high
$25.05
52-week low
$9.89

Profitability

Operating margin
2.2%
Net margin
-10.4%
EBITDA margin
-2.8%
ROE
-9.4%
ROCE
-6.6%
ROA
-6.8%
Asset turnover
0.65

Growth

Revenue
$701.2M
Revenue growth, 1Y
1.9%
Revenue CAGR, 3Y
0.8%
Net profit growth, 1Y
-81.4%
Free cash flow
$43.1M

Solvency

Current ratio
2.15
Debt / Equity
0.17
Debt / Assets
0.12
CFO / Net profit
-1.02
Cash / Market cap
7.7%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$701.2M
Cost of revenue$347.3M
Gross profit$353.9M
Operating expenses$338.5M
Research and development$23.3M
Selling, general and administrative$315.6M
Operating income$15.4M
Interest and other-$81.6M
Pretax income-$66.2M
Tax and other$6.7M
Net income-$72.9M

Revenue and net profit

Revenue grew 1.9% in FY2025; net profit is the dashed line.

Avanos Medical, Inc. revenue and net profit by fiscal year
Avanos Medical, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$684.1M$50.5M
FY2023$673.3M-$61.8M
FY2024$687.8M-$392.1M
FY2025$701.2M-$72.9M

Cash flows

FY2025: $74.7M from operations, $43.1M free after investment (dashed).

Avanos Medical, Inc. operating and free cash flow by fiscal year
Avanos Medical, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$90.9M$71.6M
FY2023$32.4M$14.6M
FY2024$100.7M$82.9M
FY2025$74.7M$43.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$701.2M+1.9%1Y
EBITDA
-$19.5M
Net profit
-$72.9M
Cash from operations
$74.7M-25.8%1Y
Free cash flow
$43.1M-48.0%1Y
Revenue CAGR, 3Y
0.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$701.2M-$19.5M-$72.9M$43.1M-9.4%+1.9%-81.4%

Monthly returns

Month-by-month returns of AVNS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$295.5M
Equity$778.2M
Paid-in capital$1.7B
Retained earnings-$779.9M
Treasury stock$102.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; AVNS highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

  1. Avanos Medical, Inc. (this company)1.7x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Avanos Medical, Inc.AVNSthis company$1.2B—1.5x-9.4%—
IRADIMED CORPORATIONIRMD$1.2B53.2x12.6x23.8%41.9x
CareDx, Inc.CDNA$1.2B-55.9x3.9x-7.0%-248.1x
Kestra Medical Technologies, Ltd.KMTS$1.2B-10.5x5.8x-55.4%-10.2x
AMN Healthcare Services, Inc.AMN$1.2B—1.8x-14.9%19.3x
Schrödinger, Inc.SDGR$1.2B-11.5x3.3x-28.4%-6.6x
Wave Life Sciences Ltd.WVE$1.2B—2.3x-39.4%—
Zenas BioPharma, Inc.ZBIO$1.2B-3.1x4.8x-156.0%-2.8x
Absci CorporationABSI$1.1B-9.9x6.0x-60.8%-10.9x
Peer median—-10.2x4.4x-33.9%-6.6x

Year-to-date ROI

AVNS since 1 January, against earlier years.

Historical volatility

AVNS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Avanos Medical, Inc. operating margin by fiscal year
Avanos Medical, Inc. operating margin by fiscal year
DateOperating margin
FY20225.2%
FY20230.6%
FY20245.9%
FY20252.2%
LineFY2025
Cost of revenueCost Of Revenue$347.3M
Gross profitGross Profit$353.9M
Operating expensesOperating Expense$338.5M
Research and developmentResearch And Development$23.3M
Selling, general and administrativeSelling General And Administration$315.6M
Other operating expensesOther Operating Expenses-$400.0k
Total expensesTotal Expenses$685.8M
Pretax incomePretax Income-$66.2M

Learn while you research

Academy chapters picked for Avanos Medical, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →